Abstract 1179P
Background
Recent reports have been shown an increased risk of de-novo malignancies in liver transplant recipients (LTRs) which is reported to be a leading cause of mortality in these patients. The aim of this systematic review and meta-analysis was to assess the prevalence of skin cancer in LTRs.
Methods
We systematically searched in five databases till 20th April 2023 through the search term ("liver transplantation" OR "liver transplant") AND ("skin cancer" OR "melanoma" OR "squamous cell carcinoma" OR "non-melanoma skin cancer" OR "post-transplant cancer" OR "post transplant cancer"). We used random effect model to overcome the significant heterogeneity we observed.
Results
A total of 34 studies, with 147154 LTRs were included. The pooled prevalence of skin cancer (all types) was 4.8% (95%confidence interval (CI): 3.6-6.5). Subgroup analysis based upon the follow up duration of each study, indicated that skin cancer prevalence increased with long duration of follow up: 0-4 years, 2.4% (95%CI: 0.5-9.9), 4-8 years, 4.2% (95%CI 2.9-6.2), and >8 years, 7.6% (95%CI: 4.7-12). Australia followed by South America had the highest prevalence of skin cancer, 20.6% (95%CI: 12.9-31.3), and 9.4% (95%CI: 5.8-14.8), in order; while Asia had the lowest prevalence 0.4% (95%CI: 0-3.8). The most common type of skin cancers was non-melanoma skin cancer reported as a combined type with a prevalence of 2.9% (95%CI: 1.1-6.9), followed by squamous cell carcinoma, basal cell carcinoma and Bowen’s cancer, 2.5% (95%CI: 1.4-4.4), 2.5% (95%CI: 1.5-4.1) and 0.8% (95%CI: 0.2-3.2), in order.
Conclusions
Consistent with what it has been reported for other organ transplants, the results from this study showed that skin cancer following liver transplantation is not rare. LTRs in Australia should receive annual dermatologic examination due to their high prevalence of skin cancers. Moreover, non-melanoma skin cancers may be the prevalent type if skin cancer is suspected in LTRs. Substantial dermatological surveillance programs are recommended in LTRs to improve quality of life as well as the associated mortality; especially with the increased prevalence after long follow up durations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13